Trending: BP Beat Market Views, Lifted Dividend Payout
1100 GMT - BP is among the most mentioned companies across news items over the past 5 hours, according to Factiva data, after the British oil-and-gas giant's second-quarter profit beat market expectations. The company reported an underlying replacement-cost profit of $2.76 billion compared with a consensus of $2.54 billion and last year's $2.59 billion, becoming the latest European energy major to exceed expectations despite weaker refining margins. Like Eni and Galp last week, BP pumped out more hydrocarbons in the quarter than it did last year amid higher crude-oil prices and stable natural-gas prices relative to the first quarter. As a result, BP hiked its quarterly dividend payout 10% to 8.00 cents a share, while it confirmed its share buyback commitment at $3.50 billion for the second half of the year. "Our decision to increase our dividend by 10%, and extend our buyback program commitment to 4Q 2024, reflects the confidence we have in our performance and outlook for cash generation," Chief Financial Officer Kate Thomson said. Dow Jones & Co. owns Factiva. (christian.moess@wsj.com)
(END) Dow Jones Newswires
July 30, 2024 07:19 ET (11:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks